{"id":32594,"date":"2021-06-02T07:00:00","date_gmt":"2021-06-02T00:00:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060207000032594"},"modified":"2021-06-02T21:39:59","modified_gmt":"2021-06-02T13:39:59","slug":"%e5%be%b7%e7%90%aa%e5%8c%bb%e8%8d%af%e5%a1%9e%e5%88%a9%e5%b0%bc%e7%b4%a215%e9%a1%b9%e7%a0%94%e7%a9%b6%e5%8f%8a%e6%88%90%e6%9e%9c%e5%b0%86%e5%9c%a82021-asco%e5%85%ac%e5%b8%83","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021060207000032594","title":{"rendered":"\u5fb7\u742a\u533b\u836f\u585e\u5229\u5c3c\u7d2215\u9879\u7814\u7a76\u53ca\u6210\u679c\u5c06\u57282021 ASCO\u516c\u5e03"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/ANTENGENE_Logo-2.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p>\u4e0a\u6d77\u548c\u9999\u6e2f2021\u5e746\u67082\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u7814\u53d1\u548c\u5546\u4e1a\u5316\u521b\u65b0\u80bf\u7624\u7597\u6cd5\u7684\u9886\u5148\u751f\u7269\u5236\u836f\u516c\u53f8<span id=\"spanHghltb2fc\">\u2014\u2014<\/span>\u5fb7\u742a\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u5fb7\u742a\u533b\u836f\u201d\uff0c\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a6996.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u540c\u7c7b\u9996\u6b3e\u9009\u62e9\u6027\u6838\u8f93\u51fa\u6291\u5236\u5242\u2014\u2014\u585e\u5229\u5c3c\u7d22\uff08selinexor\uff0915\u9879\u7814\u7a76\u53ca\u6210\u679c\u5c06\u57282021\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u5927\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u3002\u6b64\u5c4a ASCO \u4f1a\u8bae\u4e8e6\u67084\u65e5\u81f36\u67088\u65e5\u5728\u7ebf\u4e0a\u53ec\u5f00\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2756\">\n<\/p><\/div>\n<p><span id=\"spanHghltd392\"><\/span><\/p>\n<p><b>\u7ebf\u4e0a\u6458\u8981<\/b><\/p>\n<p>Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a8027<\/p>\n<p>Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated multiple myeloma.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a8024<\/p>\n<p>Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the <span class=\"xn-location\">BOSTON<\/span> study.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a8019<\/p>\n<p>Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1ae19037<\/p>\n<p>Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dosedexamethasone in Chinese patients with relapsed\/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1ae20002<\/p>\n<p>Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a8018<\/p>\n<p>SIENDO\/ENGOT-EN5\/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aTPS5610<\/p>\n<p>Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1ae15579<\/p>\n<p>A phase 1\/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aTPS2071<\/p>\n<p>A phase Ib\/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST\/GEIS-41 trial.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a11534<\/p>\n<p>Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase <span class=\"xn-money\">1b<\/span> study.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a5565<\/p>\n<p>Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a8038<\/p>\n<p>A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1aTPS8055<\/p>\n<p>Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1a11509<\/p>\n<p>Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (\u03b1CD38 mAbs).<\/p>\n<p>\u6458\u8981\u7f16\u53f7\uff1ae20020<\/p>\n<p>\u5173\u4e8e\u5fb7\u742a\u533b\u836f<\/p>\n<p>\u5fb7\u742a\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u5fb7\u742a\u533b\u836f\u201d\uff0c\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a6996.HK\uff09\u662f\u4e00\u5bb6\u4ee5\u7814\u53d1\u4e3a\u9a71\u52a8\u7684\u751f\u7269\u5236\u836f\u9886\u5148\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u4e3a\u4e9a\u592a\u4e43\u81f3\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u6700\u9886\u5148\u7684\u7597\u6cd5\uff0c\u6cbb\u7597\u80bf\u7624\u53ca\u5176\u4ed6\u5371\u53ca\u751f\u547d\u7684\u75be\u75c5\u3002\u81ea2017\u5e74\u6b63\u5f0f\u8fd0\u8425\u4ee5\u6765\uff0c\u5fb7\u742a\u533b\u836f\u901a\u8fc7\u5408\u4f5c\u5f15\u8fdb\u548c\u81ea\u4e3b\u7814\u53d1\uff0c\u5efa\u7acb\u4e86\u4e00\u6761\u4ece\u4e34\u5e8a\u524d\u5230\u4e34\u5e8a\u9636\u6bb5\u4e0d\u65ad\u5ef6\u5c55\u7684\u4e30\u5bcc\u4ea7\u54c1\u7ba1\u7ebf\u3002\u76ee\u524d\uff0c\u5fb7\u742a\u533b\u836f\u5df2\u5728\u591a\u4e2a\u4e9a\u592a\u5e02\u573a\u83b7\u5f9715\u4e2a\u4e34\u5e8a\u6279\u4ef6\uff08IND\uff09\uff0c\u5e76\u9012\u4ea4\u4e865\u4e2a\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff08NDA\uff09\u3002\u5fb7\u742a\u533b\u836f\u5c06\u4ee5\u201c\u533b\u8005\u65e0\u7586\uff0c\u521b\u65b0\u6c38\u7eed\u201d\u4e3a\u613f\u666f\uff0c\u4e13\u6ce8\u4e8e\u540c\u7c7b\u9996\u6b3e\u548c\u540c\u7c7b\u6700\u4f18\u7597\u6cd5\u7684\u65e9\u671f\u7814\u53d1\u3001\u4e34\u5e8a\u7814\u7a76\u3001\u836f\u7269\u751f\u4ea7\u53ca\u5546\u4e1a\u5316\uff0c\u89e3\u51b3\u4e9f\u5f85\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<p>http:\/\/www.antengene.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e0a\u6d77\u548c\u9999\u6e2f2021\u5e746\u67082\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u7814\u53d1\u548c\u5546\u4e1a\u5316\u521b\u65b0\u80bf\u7624\u7597\u6cd5\u7684\u9886\u5148\u751f\u7269\u5236\u836f\u516c\u53f8\u2014\u2014\u5fb7\u742a\u533b\u836f\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u5fb7\u742a\u533b\u836f\u201d\uff0c\u9999\u6e2f\u8054\u4ea4\u6240\u80a1\u7968\u4ee3\u7801\uff1a6996.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u540c\u7c7b\u9996\u6b3e\u9009\u62e9\u6027\u6838\u8f93\u51fa\u6291\u5236\u5242\u2014\u2014\u585e\u5229\u5c3c\u7d22\uff08selinexor\uff0915\u9879\u7814\u7a76\u53ca\u6210\u679c\u5c06\u57282021\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u5927\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u3002\u6b64\u5c4a ASCO \u4f1a\u8bae\u4e8e6\u67084\u65e5\u81f36\u67088\u65e5\u5728\u7ebf\u4e0a\u53ec\u5f00\u3002 \u7ebf\u4e0a\u6458\u8981 Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM). \u6458\u8981\u7f16\u53f7\uff1a8027 Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021060207000032594\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":32597,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-32594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=32594"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32594\/revisions"}],"predecessor-version":[{"id":32596,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/32594\/revisions\/32596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/32597"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=32594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=32594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=32594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}